eligibility_summary
Eligible: ECOG ≤2, CD19+ B‑cell NHL (DLBCL, HGBL, PMBCL, FL, MCL, MZL), R/R after ≥2 lines, PET/CT‑measurable disease, adequate counts/organ function. Part B: B1 R/R DLBCL after anti‑CD20+anthracycline, B2 R/R FL after anti‑CD20+alkylator, B3 other R/R B‑NHL. Exclude: CNS lymphoma, other cancers, cardiac/CNS disease, allograft, autoimmune/immunosuppression, active HBV/HCV/HIV/infection/recent live vaccines, recent HSCT/CAR‑T/CD19 TCE/antibody/chemo/RT, pregnancy, males avoid conception ≤120d.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase 1 trial of CLN-978 in relapsed/refractory B-cell non-Hodgkin lymphoma. Intervention: CLN-978, a bispecific T-cell engager antibody (drug) that binds CD19 on B cells and CD3 on T cells. Mechanism: creates an immune synapse to activate TCR/CD3 signaling, redirect endogenous T cells to proliferate and release cytotoxic granules/cytokines, killing CD19+ malignant B cells. Targets: CD19+ B cells (tumor cells) and CD3+ T cells (effectors), pathways: TCR/CD3 activation, immune synapse formation, cytotoxic apoptosis of B cells.